Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SIS-101-ADO
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Recipient : SiSaf
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SIS-101-ADO combines an siRNA that suppress expression of CLCN7, with SiSaf’s Bio-Courier® next generation silicon stabilized hybrid lipid nanoparticles technology of other RNA delivery technologies by merging LNP technology with inorganic bioabsorbab...
Brand Name : SIS-101-ADO
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : SIS-101-ADO
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Recipient : SiSaf
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?